Adam Feuerstein on Muck Rack

Adam Feuerstein Verified

As seen in:  The Street

Sr. Columnist at TheStreet, aka the Col. Jessup of biotech/drug stocks. Data Are. I curse. Said one analyst: The likes of Adam Feuerstein attack viciously.

Predicting the Outcome of the Biomarin and Sarepta FDA Drug Reviews — BOSTON ( TheStreet) -- The two leading drugs to treat Duchenne muscular dystrophy, drisapersen and eteplirsen, are accepted officially for priority review by the U.S. Food and Drug Administration. With the intrigue about regulatory filings out of the way, investors can now focus solely on what really matters -- the outcome of the FDA reviews and the impact on the drugs' respective sponsors Biomarin Pharmaceuticals and Sarepta Therapeutics .
Aug 27, 2015

Predicting the Outcome of the $BMRN and $SRPT FDA Drug Reviews… Here's what happens to drisa and etep

An Inside Look at Biotech Investor Pros Dealing With Market Meltdown — BOSTON ( TheStreet) -- Last night, I exchanged emails with a number of investors who run dedicated healthcare funds. I wanted to know how they navigated Monday's market sell off. Were they selling? Buying? Did the extreme volatility in stock prices Monday force them to do anything different?

Biotech Stocks Recover From Early-Morning Flash Crash — NEW YORK (TheStreet) -- It could be worse. A lot worse. Biotech and pharma stocks crashed early amidst a global market sell off but are recovering mid-day. Some sentinel stocks -- Gilead Sciences , Celgene , Bristol-Myers Squibb and Vertex Pharma -- are actually trading a tiny bit higher or down fractionally.
Aug 24, 2015

Biotech Stocks Recover From Early-Morning Flash Crash… Publishing this story guarantees another flash crash, natch.

Northwest Bio (NWBO) Forced to Temporarily Halt Study of Brain Tumor Vaccine — BETHESDA, Md. ( TheStreet) -- Northwest Biotherapeutics confirmed on Friday that it has temporarily halted a phase III clinical trial involving its brain tumor vaccine DCVax-L. Enrollment of new patients into the DCVax-L study has been suspended until the company "submits certain information from the trial for regulatory review," Northwest Bio said in a statement.
Aug 24, 2015

$NWBO Forced to Temporarily Halt Study of Brain Tumor Vaccine… + helpful reminder of myriad delays/setbacks for DCVax

Biotech Stock Mailbag: Celldex (CLDX), Bluebird (BLUE), Kite (KITE), Inovio (INO) — BOSTON ( TheStreet) -- This is the "I took a vacation and stuff happened" Biotech Stock Mailbag. Manish R. emails, "You've been quite bullish on Celldex Therapeutics in the past so I was surprised when you didn't comment at all on the company's recent setback as it relates to Rintega and the lack of an [FDA] accelerated approval application.

MannKind Financial Woes Escalate on Failed Debt Settlement — VALENCIA, Calif. (TheStreet) -- MannKind failed to settle a $100 million convertible loan before an August 15 deadline. The embattled diabetes-drug company is trying a second time to clear the debt but on even less favorable terms, which will bleed off a larger chunk of cash.

Biotech Stocks Get Burned This Summer, but Fall Might Bring Relief — BOSTON ( TheStreet) -- I'm back at work after a nice, 10-day vacation. I had great time away from biotech stocks, thanks for asking. It doesn't look like I missed much in the news department, but valuations of biotech stocks are nearing a 10% decline that would put them in correction territory.
Aug 19, 2015

Biotech Stocks Get Burned This Summer, but Fall Might Bring Relief… The $BLUE flu is infecting others SMID stocks

Biotech Stock Mailbag: Controversial Stocks Revisited — BOSTON ( TheStreet) -- We're in the August lull, so this week's Biotech Stock Mailbag revisits and updates some past, controversial stories. @adamfeuerstein Receptos getting lots of attention with autoimmune and S1P1 -P5 agonist. How about ARNA APD334? - K Caudy (@KKC56) July 22, 2015 Arena Pharmaceuticals' best (last?)

Seven Reasons to Love Biomarin's Duchenne Drug Falls One Short — NEW YORK ( TheStreet) -- RBC Capital analyst Michael Yee offers seven reasons why Biomarin Pharmaceuticals will secure U.S. approval for drisapersen to treat Duchenne muscular dystrophy, a rare, genetic muscle-wasting disease. Yee predicts a 65% chance of drisapersen's approval by the end of the year.

Intra-Cellular (ITCI) Keeps Investors in Dark About Schizophrenia Drug Study — NEW YORK (TheStreet) -- Intra-Cellular Therapies has a poster problem. The poster contains a full presentation of data from a phase II study of Intra-Cellular's experimental schizophrenia drug ITI-007. Kim Vanover, the company's top scientist, presented the ITI-007 data poster in May at the American Psychiatric Association annual meeting.
More Articles →
Aug 28, 2015

I'm watching a pre-season football game. Yes, I'm a loser but Go Pats!!! Loser loser loser loser loser loser loser

Aug 28, 2015

@JohnCFierce Perhaps first on Twitter, but only after $ARIA had already moved higher, so someone else had thought first. Thx, john.

Aug 28, 2015

$IBB +4% for week is not what most would have predicted on Sunday-Monday.

Aug 28, 2015

. @dsobek Adding $ARIA, if that’s the buy, doesn’t improve $BXLT much. But then, that might suggest dis-interest from better targets.

Aug 28, 2015

. @dsobek Have you looked at $BXLT current oncology pipeline? Mediocre. Boring. Adding anything would be an improvement.

Aug 28, 2015

That $BXLT report is via Bloomberg, by the way.

Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.